用AI从零设计抗体，OpenAI支持的Chai Discovery获1.3亿美元融资

Group 1 - Chai Discovery, a biotechnology startup backed by OpenAI, announced a Series B funding round of $130 million, raising its valuation to $1.3 billion [1][3] - The funding round was led by General Catalyst and Oak HC/FT, with participation from several investors including Menlo Ventures, OpenAI, and others, bringing the total funding raised by the company to over $225 million [3] - The company focuses on drug discovery, leveraging artificial intelligence to accelerate the drug development process, with its models predicting interactions between biochemical molecules [3] Group 2 - Chai Discovery aims to create a "molecular computer-aided design suite" and has launched its latest AI model, Chai 2, which shows significant improvement in the de novo design of antibodies [4] - The CEO, Josh Meier, stated that the new model can design molecules with ideal drug properties, addressing previously challenging targets [4] - Chai Discovery was founded in 2024, and its CEO has a background in machine learning, having previously worked at Facebook and OpenAI [4]